GlassScriptPhysician profile
Endia Mcdonald
NPI 1689291825
$1,447.11
in general payments reported to CMS, 2019-2025
17 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $142 · 2023: $889 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,306.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $244.67 | 2022-2025 | Caplyta |
| Abbvie INC. | $197.38 | 2023-2025 | |
| Alkermes, INC. | $156.01 | 2023-2025 | Lybalvi |
| Janssen Pharmaceuticals, INC | $132.23 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $92.92 | 2023 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $90.12 | 2023-2025 | Abilify Maintena, Rexulti |
| Neos Therapeutics, LP | $70.02 | 2023-2025 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $62.01 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $61.25 | 2023-2025 | Trintellix |
| Corium, LLC | $58.23 | 2022-2023 | Azstarys |
| Tris Pharma INC | $57.19 | 2023-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $54.48 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $50.27 | 2023-2025 | Ingrezza |
| Noven Therapeutics, LLC | $46.60 | 2023 | Xelstrym |
| Almatica Pharma LLC | $28.34 | 2025 | Loreev Xr |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.58 | 2023 | Belsomra |
| Bausch Health US, LLC | $21.81 | 2025 | Aplenzin, Wellbutrin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Endia Mcdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.